Title: Rxsight, Inc. (RXST) 10K Annual Reports & 10Q SEC Filings
URL: https://last10k.com/sec-filings/rxst

HOME


LOGIN


PREMIUM


FREE TRIAL


SEC FILINGS


STOCK SCREENERS


EARNINGS


TRENDING


STOCKTWITS


INSIDER TRADING


SENTIMENT ANALYSIS


MANAGER PORTFOLIOS


LATE CORPORATE NEWS






				 



Rxsight, Inc. (RXST) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023


Home
SEC Filings
Rxsight, Inc. (RXST)
10-K Annual Report Wed Feb 28 2024






SEC Filings



 
RXST Valuations





Intrinsic Value





Financial Stability





Financial Ratios





Insider Trades





Manager Portfolios





Notifications





 
RXST Annual Reports
				  





10-K Annual Report February 2024


PDF

PDF


Select PDF Feature:
Include Exhibits
Highlight YoY Changes
Highlight Sentiment

10-K Only


Word
Excel
CSV


Table of Contents
Business
Risk Factors
Unresolved Staff Comments
Cybersecurity
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Managements Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accountant Fees and Services
Exhibit and Financial Statement Schedules
Form 10K Summary








									10-K Annual Report March 2023																






									10-K Annual Report March 2022																






RXST Quarterly Reports
				  





									10-Q Quarterly Report August 2024																






									10-Q Quarterly Report May 2024																






									10-Q Quarterly Report November 2023																






									10-Q Quarterly Report August 2023																






									10-Q Quarterly Report May 2023																






									10-Q Quarterly Report November 2022																






									10-Q Quarterly Report August 2022																






									10-Q Quarterly Report May 2022																






									10-Q Quarterly Report November 2021																






RXST Corporate News
				  





									Earnings Release																	August 2024







									Vote of Security Holders																	June 2024







									Financial ExhibitNew AgreementOther Events																	May 2024







									Earnings ReleaseFinancial Exhibit																	May 2024







									New Agreement																	April 2024







									Earnings Release																	February 2024







									Earnings Release																	January 2024







									Earnings ReleaseFinancial Exhibit																	November 2023







									Earnings ReleaseFinancial Exhibit																	August 2023







									Ending AgreementFinancial ExhibitNew AgreementNew Financial ObligationSecurity Holders Change																	July 2023













Last10K.com | 10-K Annual Report Wed Feb 28 2024






Rxsight, Inc.


													CIK: 1111485
																										Ticker: RXST




Earnings Press Release
 10-K Annual Report
 10-K YoY Changes
 Annual Proxy




Rxsight, Inc.

HISTORY
TOOLS


CIK: 1111485
Ticker: RXST




  Exhibit 99.1   RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – February 28, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023.Key Quarterly and Full Year Highlights •Recognized fourth quarter 2023 revenue of $28.6 million, an increase of 78% compared to the fourth quarter of 2022, reflecting:•The sale of 77 Light Delivery Devices (LDDs), representing a 35% unit increase from the fourth quarter of 2022, expanding the installed base to 666 LDDs at the end of the quarter, a 67% increase compared to the 400-unit LDD installed base at the end of the fourth quarter of 2022; and•The sale of 18,071 Light Adjustable Lenses (LAL®s), representing a 98% increase in procedure volumes compared to the fourth quarter of 2022.•Recognized full-year 2023 revenue of $89.1 million, representing growth of 82% compared to 2022, driven by unit sales of 266 LDDs and 54,873 LALs, representing increases of 36% and 117%, respectively, compared to 2022.“We are very thankful to all our partner doctors and practices for joining with the RxSight team to consistently deliver high-quality vision across a range of distances,” said Ron Kurtz, CEO and President of RxSight. “As we step into 2024, we aim to expand our ability to optimize premium cataract surgery by unlocking the full potential of adjustable technology for patients.” Fourth Quarter Financial Results In the fourth quarter of 2023, total revenue was $28.6 million, an increase of 78% compared to the fourth quarter of 2022. Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.Gross profit for the fourth quarter of 2023 was $17.7 million or 62% of revenue, an increase of $10.2 million or 138% compared to gross profit of $7.4 million or 46% of revenue for the fourth quarter of 2022. The increase in gross profit was due to a favorable product mix from a greater percentage of revenue from LAL sales and sales of the LDD with a lower cost to manufacture and a higher average selling price.Total operating expenses for the fourth quarter of 2023 were $28.5 million, a 27% increase from $22.4 million in the fourth quarter of 2022, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL procedure volumes.In the fourth quarter of 2023, the company reported a net loss of $(9.2) million, or $(0.26) per basic and diluted share, compared to a net loss of $(15.6) million, or $(0.56) per share on a basic and diluted basis in the fourth quarter of 2022. Adjusted net loss in the fourth quarter of 2023 was $(4.8) million, or  
The following information was filed by Rxsight, Inc. (RXST) on Wednesday, February 28, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release. 

Please wait while we load the requested 10-K report or click the link below:https://last10k.com/sec-filings/report/1111485/000095017024022073/rxst-20231231.htm


View differences made from one year to another to evaluate Rxsight, Inc.'s financial trajectory





Sample 10-K Year-over-Year (YoY) Comparison



Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Rxsight, Inc..

Continue







Assess how Rxsight, Inc.'s management team is paid from their Annual Proxy





Screenshot example of actual Proxy Statement




Rxsight, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors


Continue














SEC Filing Tools




 Sentiment
 Sections
 Exhibits
 Stats


 



 Rating					
Learn More










Filter Sentiment:



All






Positive




Negative





Filter Category:




All





Financial







Revenue






M & A






Legal






Other






Filter Subcategory:




All






Cash Flow






Expense






Product






Geography






Debt






Shares





Earnings







Income






Other







 Inside Rxsight, Inc.'s 10-K Annual Report:


 Other - Other   Highlight
Uncertain macroeconomic conditions including recent inflationary pressures and the rise in interest rates have created significant uncertainty in the U.S. economy and capital markets, which is expected to continue through 2024 and beyond and could negatively impact our financial results and liquidity.



 Financial - Cash Flow   Highlight
We have incurred significant operating losses and negative cash flows from operations since our inception, and we anticipate that we will incur significant losses in the future.

 Financial - Cash Flow   Highlight
Because of these and other factors, we expect to continue to incur net losses and negative cash flows from operations in the near future.

 Other - Other   Highlight
Pursuant to these arrangements, we indemnify, hold harmless and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement, misappropriation or other violation claim by any third party with respect to its technology.

 Other - Other   Highlight
If the doctor’s prediction isn’t exact, the patient may experience suboptimal results that could necessitate a subsequent corneal refractive procedure or certain other compromises in order to reach vision targets.

 Other - Other
Any supply interruption from our...Read more

 Financial - Expense
While we depend on our...Read more

 Other - Other
The maximum potential amount of...Read more

 Revenue - Product
The LDD capital asset and...Read more

 Financial - Expense
We expect SG&A expenses to...Read more

 Other - Other
We plan to grow our...Read more

 Revenue - Product
The increase was due to...Read more

 Revenue - Geography
Comprehensive loss is defined as...Read more

 Revenue - Product
During 2023, we had increased...Read more

 Financial - Expense
To continue to strengthen our...Read more

 Revenue - Product
Revenue is recognized for LALs...Read more

 Revenue - Product
Revenue is recognized for LALs...Read more

 M & A - Other
Finally, we may in the...Read more

 Other - Other
On August 8, 2022, we...Read more

 Revenue - Product
Revenue is recognized from sales...Read more

 Revenue - Product
We believe the number of...Read more

 Other - Other
Certain suppliers have passed on...Read more

 Other - Other
As of December 31, 2023,...Read more

 Other - Other
We believe the number of...Read more

 Other - Other
We regularly review several operating...Read more

 Revenue - Product
We believe our RxSight system...Read more

 Revenue - Product
We believe this business model...Read more

 Financial - Debt
The shelf registration is effective...Read more

 Financial - Shares
On February 7, 2023, we...Read more

 Financial - Expense
The preparation of these financial...Read more

 Financial - Earnings
Gross margin increased to 60.4%...Read more

 Financial - Debt
Debt financing and preferred equity...Read more

 Revenue - Geography
Our RxSight system is approved...Read more

 Other - Other
We may be unable to...Read more

 Revenue - Product
We intend to continue to...Read more

 Financial - Shares
Under the terms of the...Read more

 Other - Other
After the first year, service...Read more

 Revenue - Product
Our United States commercial organization...Read more

 Revenue - Product
We intend to continue to...Read more

 Other - Other
We will expand our marketing...Read more

 Revenue - Product
The timing of revenue recognition...Read more

 Other - Other
our ability to maintain, expand,...Read more

 Other - Other
The May 2022 LSA increased...Read more

 Revenue - Product
Our commercial efforts began in...Read more

 Financial - Shares
On the last business day...Read more

 Revenue - Product
Our sales consist of the...Read more

 Other - Other
We may selectively pursue commercial...Read more

 Financial - Expense
Our LDD, as is typical...Read more

 Revenue - Product
We believe selectively increasing the...Read more

 Other - Other
We do not have long-term...Read more

 Financial - Expense
The expenses include personnel-related expenses,...Read more

 Revenue - Product
our ability to retain our...Read more

 Other - Other
The shelf registration statement was...Read more

 Other - Other
We enter into standard indemnification...Read more

 Revenue - Product
As our manufacturing volume of...Read more

 Revenue - Product
We expect revenue to increase...Read more

 Other - Other
For the years ended December...Read more

 Financial - Expense
Cost of sales consist of...Read more

 Legal - Other
We are a Delaware corporation...Read more

 Other - Other
We believe the number of...Read more

 Financial - Expense
We expect cost of sales...Read more

 Other - Other
Our LDD contracts contain multiple...Read more

 Revenue - Product
Our fourth quarter of 2023...Read more

 Other - Other
On August 4, 2023, we...Read more

 Other - Other
As a result, as of...Read more

 Revenue - Product
We designed our RxSight system...Read more

 Other - Other
We utilize purchase orders or...Read more

 Other - Other
We may not yet be...Read more

 Other - Other
In addition, we do not...Read more

 Revenue - Geography
The wholly owned subsidiary has...Read more

 Legal - Other
We have never incurred costs...Read more

 Other - Other
Although we lost our status...Read more

 Other - Other
Additional development and clinical studies...Read more

 Other - Other
We believe that our current...Read more

 Financial - Shares
If we raise additional funds...Read more

 Revenue - Product
Our revenue is generated from...Read more

 Other - Other
The underwriters' option was exercised...Read more

 Financial - Shares
If we determine that we...Read more

 Other - Other
Our estimates are based on...Read more

 Other - Other
The aggregate amount of the...Read more

 Financial - Expense
the outcome, costs and timing...Read more

 Revenue - Geography
New approvals may also be...Read more

 Financial - Earnings
Our gross margin has been...Read more

 Revenue - Product
Our sales efforts are concentrated...Read more

 Revenue - Product
Competitive premium IOLs require patients...Read more

 Financial - Shares
Although, based on our current...Read more

 Other - Other
We also previously qualified as...Read more

 Financial - Shares
To the extent that we...Read more

 Other - Other
The term of these indemnification...Read more

 Revenue - Product
The LAL is a premium...Read more

 Financial - Expense
Additionally, due to these supply...Read more

 Other - Other
The expansion of global lead...Read more

 Revenue - Product
Premium IOLs are sold at...Read more

 Revenue - Product
For the year ended December...Read more

 Financial - Earnings
Our gross margin could fluctuate...Read more

 Financial - Expense
Cost of sales also includes...Read more

 Revenue - Product
Once a patient has selected...Read more

 Other - Other
We rely on third parties,...Read more

 Financial - Debt
our ability to borrow or...Read more

 Financial - Expense
The paydown in full of...Read more

 Financial - Expense
Selling, general and administrative (“SG&A”),...Read more

 Financial - Expense
Interest expense consist primarily of...Read more

 Other - Other
If we are unable to...Read more

 Revenue - Product
Revenue recognition is reasonably likely...Read more

 Financial - Income
Interest and other income, net...Read more

 Financial - Expense
We expect research and development...Read more

 Revenue - Product
We recognize LDD revenue primarily...Read more

 Financial - Debt
Loss on extinguishment of term...Read more

 Financial - Expense
Research and development expenses consist...Read more

 Revenue - Geography
Our ability to raise additional...Read more

 Other - Other
We also have a standby...Read more

 Financial - Expense
We will also continue to...Read more

 Other - Other
These agreements may require that...Read more

 Other - Other
While we have taken measures...Read more

 Other - Other
Our near-term research and development...Read more

 Other - Other
the terms and timing of...Read more

 Other - Other
Moreover, in the event that...Read more

 Financial - Cash Flow
Actual results may differ from...Read more

 Financial - Expense
Overhead costs include the cost...Read more



 
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report





Document And Entity Information





Consolidated Balance Sheets





Consolidated Balance Sheets (Parenthetical)





Consolidated Statements Of Cash Flows





Consolidated Statements Of Operations And Comprehensive Loss





Consolidated Statements Of Redeemable Common Stock, Stock Options, Convertible Preferred Stock And Stockholders' Equity (Deficit)





Accrued Expenses And Other Current Liabilities





Accrued Expenses And Other Current Liabilities (Tables)





Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expenses And Other Current Liabilities (Details)





Commitments And Contingencies





Commitments And Contingencies - Additional Information (Details)





Common Stock Warrant Liability - Additional Information (Details)





Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)





Convertible Preferred Stock Warrants - Schedule Of Probability Weighted Assumptions Of Convertible Preferred Stock Warrants (Details)





Employee Benefit Plan





Employee Benefit Plan - Additional Information (Details)





Fair Value Measurements





Fair Value Measurements (Tables)





Fair Value Measurements - Schedule Of Assets And Liabilities Measured At Fair Value On Recurring Basis And The Fair Value Hierarchy Of The Valuation Techniques (Details)





Income Tax - Schedule Of Deferred Tax Assets (Details)





Income Taxes





Income Taxes (Tables)





Income Taxes - Additional Information (Details)





Income Taxes - Schedule Of Components Of Income Tax Expense (Benefit) (Details)





Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Details)





Income Taxes - Schedule Of Income Before Income Tax (Details)





Income Taxes - Schedule Of Unrecognized Tax Benefits Roll Forward (Details)





Inventories





Inventories (Tables)





Inventories - Additional Information (Details)





Inventories - Schedule Of Inventories (Details)





Leases





Leases (Tables)





Leases - Additional Information (Details)





Leases - Schedule Of Components Of Lease Expense (Details)





Leases - Schedule Of Maturities Of Lease Liabilities (Details)





Leases - Summary Of Lease Balances Sheet Information (Details)





Leases - Summary Of Weighted Average Remaining Lease Term And Discount Rate (Details)





Organization And Basis Of Presentation





Organization And Basis Of Presentation - Additional Information (Details)





Property And Equipment





Property And Equipment (Tables)





Property And Equipment - Additional Information (Details)





Property And Equipment - Schedule Of Property And Equipment (Details)





Short-Term Investments





Short-Term Investments (Tables)





Short-Term Investments - Additional Information (Details)





Short-Term Investments - Schedule Of Short-Term Investment Available For Sale (Details)





Stock-Based Compensation Expense





Stock-Based Compensation Expense (Tables)





Stock-Based Compensation Expense - Additional Information (Details)





Stock-Based Compensation Expense - Schedule Of Range And Weighted-Average Assumptions Used In Black-Scholes Option Pricing Model To Determine The Fair Value Of Stock Options (Details)





Stock-Based Compensation Expense - Schedule Of Stock-Based Compensation Expense (Details)





Stock-Based Compensation Expense - Summary Of Non-Vested Restricted Stock Unit Activities (Details)





Stock-Based Compensation Expense - Summary Of Stock Option Activities (Details)





Stockholders Equity (Deficit)





Stockholders Equity (Deficit) (Tables)





Stockholders Equity (Deficit) - Additional Information (Details)





Stockholders Equity (Deficit) - Summary Of Common Stock Reserved For Future Issuance (Details)





Stockholders Equity (Deficit) - Summary Of Preferred Units (Details)





Stockholders' Equity - Summary Of Common Stock Reserved For Future Issuance (Parenthetical) (Details)





Subsequent Events - Additional Information (Details)





Summary Of Accounting Policies





Summary Of Accounting Policies (Policies)





Summary Of Accounting Policies (Tables)





Summary Of Accounting Policies - Additional Information (Details)





Summary Of Accounting Policies - Schedule Of Cash Cash Equivalents And Restricted Cash (Details)





Summary Of Accounting Policies - Schedule Of Deferred Revenue Activity (Details)





Summary Of Accounting Policies - Schedule Of Dilutive Securities Excluded From Computation Of Income (Loss) Per Share (Details)





Summary Of Accounting Policies - Schedule Of Revenue From Contracts With Customers (Details)





Term Loan





Term Loan - Additional Information (Details)





Term Loan - Future Annual Principal Payments Due Under The Amended Term Loan (Details)




 
Material Contracts, Statements, Certifications & more
Rxsight, Inc. provided additional information to their SEC Filing as exhibits





Exhibit 10.27: Material Contract





Exhibit 23.1: Consents Of Experts And Counsel





Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 32.1: Section 1350 Certification





Exhibit 32.2: Section 1350 Certification





Exhibit 97.1: Ex-97.1






Ticker: RXST CIK: 1111485
Form Type: 10-K Annual Report
Accession Number: 0000950170-24-022073
Submitted to the SEC: Wed Feb 28 2024 4:10:44 PM EST
Accepted by the SEC: Wed Feb 28 2024
Period:  Sunday, December 31, 2023
Industry: Ophthalmic Goods						
External Resources:
 Stock Quote
 Social Media
 SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/rxst/0000950170-24-022073.htm








About 
											Contact 
											Help 
											API 
											Privacy 
											Terms 
									


© 2012 - 2024 Last10K.com All Rights Reserved









×
You're Signed Out
Sign in for the full experience


Sign in
Join Now








Intrinsic Value Calculator








Screenshot of intrinsic value for AT&T (2019)




Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
Continue












Never Miss A New SEC Filing Again








Screenshot taken from Gmail for a new 10-K Annual Report




Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news
Continue












We Highlighted This SEC Filing For You








Screenshot taken from Wynn's 2018 10-K Annual Report




Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q
Continue












Widen Your SEC Filing Reading Experience








Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report




Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view
Continue












Uncover Actionable Information Inside SEC Filings








Screenshot taken from Lumber Liquidators 10-K Annual Report




Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Financial Stability Report








Screenshot of financial stability report for Coco-Cola (2019)




Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
Continue












Get a Better Picture of a Company's Performance








Available Financial Ratios




Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years
Continue












See when company executives buy or sell their own stock








Screenshot taken from Euronet (EEFT)




Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings
Continue












See how institutional managers trade a stock








Screenshot taken from General Motors (GM)




Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more
Continue












FREE Financial Statements








Screenshot of actual balance sheet from company 10-K Annual Report




Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREE












SEC Filing Exhibit
 PDF Download



Loading SEC Filing Exhibit...








SEC Filing Financial Summary
 PDF Download
 Excel Download



Loading SEC Filing Financial Summary...

